STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.
   PubMed Web of Science ®Google Scholar
• Schneider C, Pasqualucci L, Dalla-Favera R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol. 2011;28(2):167–177.
   PubMed Web of Science ®Google Scholar
• Miao Y, Medeiros LJ, Li Y, et al. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16(10):634.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298–310.
   PubMed Web of Science ®Google Scholar
• Barta SK, Samuel MS, Xue X, et al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol. 2015;26(5):958–966.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Mulder TA, Wahlin BE, Osterborg A, et al. Targeting the immune microenvironment in lymphomas of B-cell origin: from biology to clinical application. Cancers (Basel). 2019;11:pii: E915.
   Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444.
   PubMed Web of Science ®Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105–115.
   PubMed Web of Science ®Google Scholar
• Kujawski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008;118(10):3367–3377.
   PubMed Web of Science ®Google Scholar
• Ding BB, Yu JJ, Yu RY, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2007;111(3):1515–1523.
   PubMed Web of Science ®Google Scholar
• Ok CY, Chen J, Xu-Monette ZY, et al. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res. 2014;20(19):5113–5123.
   PubMed Web of Science ®Google Scholar
• Wu ZL, Song YQ, Shi YF, et al. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol. 2011;4:31.
   PubMed Web of Science ®Google Scholar
• Tamma R, Ingravallo G, Albano F, et al. STAT-3 RNAscope determination in human diffuse large B-cell lymphoma. Transl Oncol. 2019;12(3):545–549.
   PubMed Web of Science ®Google Scholar
• Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111(7):3701–3713.
   PubMed Web of Science ®Google Scholar
• Marinaccio C, Ingravallo G, Gaudio F, et al. Microvascular density, CD68 and tryptase expression in human diffuse large B-cell lymphoma. Leuk Res. 2014;38(11):1374–1377.
   PubMed Web of Science ®Google Scholar
• Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–746.
   PubMed Web of Science ®Google Scholar
• Avalle L, Camporeale A, Camperi A, et al. STAT3 in cancer: a double edged sword. Cytokine. 2017;98:42–50.
   PubMed Web of Science ®Google Scholar
• Ruggieri S, Tamma R, Resta N, et al. Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma. Oncotarget. 2017;8(19):31254–31269.
   PubMedGoogle Scholar
• Yuan J, Zhang F, Niu R. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep. 2016;5(1):17663.
   Google Scholar
• Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res. 2003;9(1):316–326.
   PubMed Web of Science ®Google Scholar
• Lin L, Liu A, Peng Z, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 2011;71(23):7226–7237.
   PubMed Web of Science ®Google Scholar
• Chang Q, Bournazou E, Sansone P, et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia. 2013;15(7):848–862.
   PubMed Web of Science ®Google Scholar
• Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013;2013:1.
   Google Scholar
• Matsukawa A, Kudo S, Maeda T, et al. Stat3 in resident macrophages as a repressor protein of inflammatory response. J Immunol. 2005;175(5):3354–3359.
   PubMed Web of Science ®Google Scholar
• Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Mol Interv. 2011;11(1):18–26.
   PubMedGoogle Scholar
• Gritsina G, Xiao F, O'Brien SW, et al. Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma growth. Mol Cancer Ther. 2015;14(4):1035–1047.
   PubMed Web of Science ®Google Scholar
• Sgrignani J, Garofalo M, Matkovic M, et al. Structural biology of STAT3 and its implications for anticancer therapies development. Int J Mol Sci. 2018;19:pii: E1591.
   Web of Science ®Google Scholar
• Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014;1845:136–154.
   PubMed Web of Science ®Google Scholar
• Lu L, Zhu F, Zhang M, et al. Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2018;115(3):E498–E505.
   PubMed Web of Science ®Google Scholar
• Gouilleux-Gruart V, Gouilleux F, Desaint C, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 1996;87(5):1692–1697.
   PubMed Web of Science ®Google Scholar
• Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997;100(12):3140–3148.
   PubMed Web of Science ®Google Scholar
• Munoz J, Dhillon N, Janku F, et al. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist. 2014;19(5):536–544.
   PubMed Web of Science ®Google Scholar
• Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905–1913.
   PubMed Web of Science ®Google Scholar
• Shahmarvand N, Nagy A, Shahryari J, et al. Mutations in the signal transducer and activator of transcription family of genes in cancer. Cancer Sci. 2018;109(4):926–933.
   PubMed Web of Science ®Google Scholar
• Hu J, Hu WX. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments. Cancer Lett. 2018;414:214–221.
   PubMed Web of Science ®Google Scholar
• Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23(1):10–24.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Kimlinger T, Haug J, et al. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol. 2010;85(9):675–686.
   PubMed Web of Science ®Google Scholar
• Kannaiyan R, Hay HS, Rajendran P, et al. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol. 2011;164(5):1506–1521.
   PubMed Web of Science ®Google Scholar
• Takeda T, Tsubaki M, Tomonari Y, et al. Bavachin induces the apoptosis of multiple myeloma cell lines by inhibiting the activation of nuclear factor kappa B and signal transducer and activator of transcription 3. Biomed Pharmacother. 2018;100:486–494.
   PubMed Web of Science ®Google Scholar
• Hu L, Wu H, Li B, et al. Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 2017;49(5):420–427.
   PubMed Web of Science ®Google Scholar
• Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;101(2):681–689.
   PubMed Web of Science ®Google Scholar
• Mackenzie GG, Queisser N, Wolfson ML, et al. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer. 2008;123(1):56–65.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yang Z, Jia Z, et al. ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex. Mol Cancer. 2014;13(1):181.
   PubMedGoogle Scholar
• Zhao X, Zhang Z, Moreira D, et al. B cell lymphoma immunotherapy using TLR9-targeted oligonucleotide STAT3 inhibitors. Mol Ther. 2018;26(3):695–707.
   PubMed Web of Science ®Google Scholar
• Mitchell TJ, John S. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology. 2005;114(3):301–312.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Ribatti D. Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. Immunol Lett. 2013;152(2):83–88.
   PubMed Web of Science ®Google Scholar
• Iriki T, Ohnishi K, Fujiwara Y, et al. The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation. Lung Cancer. 2017;106:22–32.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zeng Y, Qu Q, et al. PD-L1 induced by IFN-gamma from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol. 2017;22(6):1026–1033.
   PubMed Web of Science ®Google Scholar
• Tamma R, Ruggieri S, Annese T, et al. Bcl6/p53 expression, macrophages/mast cells infiltration and microvascular density in invasive breast carcinoma. Oncotarget. 2018;9(32):22727–22740.
   PubMedGoogle Scholar
• Harris JA, Jain S, Ren Q, et al. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol. 2012;7(1):12.
   PubMedGoogle Scholar
• Jeong J, Oh EJ, Yang WI, et al. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma. Hum Pathol. 2017;64:222–231.
   PubMed Web of Science ®Google Scholar
• Wang J, Gao K, Lei W, et al. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes. Oncotarget. 2017;8:5414–5425.
   PubMedGoogle Scholar
• Guo Q, Jin Z, Yuan Y, et al. New mechanisms of tumor-associated macrophages on promoting tumor progression: recent research advances and potential targets for tumor immunotherapy. J Immunol Res. 2016;2016:1.
   Google Scholar
• Kridel R, Steidl C, Gascoyne RD. Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica. 2015;100(2):143–145.
   PubMed Web of Science ®Google Scholar
• Chen Z, Deng X, Ye Y, et al. Novel risk stratification of de novo diffuse large B cell lymphoma based on tumour-infiltrating T lymphocytes evaluated by flow cytometry. Ann Hematol. 2019;98(2):391–399.
   PubMed Web of Science ®Google Scholar
• Xu Y, Kroft SH, McKenna RW, et al. Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br J Haematol. 2001;112(4):945–949.
   PubMed Web of Science ®Google Scholar